FDA Adverse Event Injury Summary report: N

XIENCE PRIME EVEROLIMUS ELUTING CORONARY STENT SYSTEM

MDR report key: 3131966 · Received May 29, 2013

Report

Report Number
2024168-2013-03328
Event Type
Injury
Date Received
May 29, 2013
Date of Event
May 3, 2013
Report Date
May 3, 2013
Manufacturer
AV-TEMECULA-CT
Product Code
NIQ
PMA / PMN Number
P110019
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
AS
Reporter Occupation
HEALTH PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

(B)(4). DURING PROCESSING OF THIS COMPLAINT, ATTEMPTS WERE MADE TO OBTAIN COMPLETE EVENT, PATIENT AND DEVICE INFORMATION. THE STENT REMAINS IN THE ANATOMY. INVESTIGATION IS NOT YET COMPLETE. A FOLLOW-UP REPORT WILL BE SUBMITTED WITH ALL ADDITIONAL RELEVANT INFORMATION.

Additional Manufacturer Narrative · 1

(B)(4). THERE WERE NO REPORTED PRODUCT DEFICIENCIES. THE REPORTED PATIENT EFFECT OF STENOSIS/RESTENOSIS IS LISTED IN THE XIENCE PRIME EVEROLIMUS ELUTING CORONARY STENT SYSTEM INSTRUCTIONS FOR USE AS A KNOWN PATIENT EFFECT OF CORONARY STENTING PROCEDURES. ALTHOUGH A CONCLUSIVE CAUSE FOR THE REPORTED PATIENT EFFECT AND THE RELATIONSHIP TO THE DEVICE IF ANY CANNOT BE DETERMINED, THERE IS NO INDICATION OF A PRODUCT QUALITY DEFICIENCY WITH RESPECT TO MANUFACTURE, DESIGN, OR LABELING.

Description of Event or Problem · 1

IT WAS REPORTED THAT DURING THE PROCEDURE IN THE CIRCUMFLEX ARTERY, RESTENOSIS (30-40%) OF A 2.75X15 RX XIENCE PRIME STENT PREVIOUSLY IMPLANTED IN THE LEFT ANTERIOR DESCENDING ARTERY WAS DIAGNOSED. NO TREATMENT FOR THE RESTENOSIS WAS PERFORMED AS THE PHYSICIAN FELT THE ARTERY WAS STILL OPEN ENOUGH. THE PROCEDURE WAS BEING PERFORMED FOR TREATMENT OF THE SIGNIFICANT LESION IN THE CIRCUMFLEX AND THE RESTENOSIS DID NOT CAUSE THE PATIENT TO RETURN FOR TREATMENT. NO ADDITIONAL INFORMATION WAS PROVIDED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
234437 XIENCE PRIME EVEROLIMUS ELUTING CORONARY STENT SYSTEM DRUG ELUTING CORONARY STENT SYSTEM NIQ AV-TEMECULA-CT 2081641

Patients

Seq Age Sex Outcome Treatment
1 63 YR Other